Characterization of distinct types of <i>KRAS</i> mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer.

Oncol Lett · 2017 · PMC5686437 · PMID 29163686

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

marginally statistically significantP=0.051so close (0.05 < p ≤ 0.1)

In addition, there was a shorter but marginally statistically significant progression-free survival (PFS) in KRAS mutant patients with adenocarcinoma compared with those with non-adenocarcinoma (P=0.051).

also in 1,110 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.